| Literature DB >> 28604617 |
Irina Belyanina1, Olga Kolovskaya2,3, Sergey Zamay4, Ana Gargaun5, Tatiana Zamay6,7, Anna Kichkailo8,9.
Abstract
Current advances in targeted magnetic nanotheranostics are summarized in this review. Unique structural, optical, electronic and thermal properties of magnetic materials in nanometer scale are attractive in the field of biomedicine. Magnetic nanoparticles functionalized with therapeutic molecules, ligands for targeted delivery, fluorescent and other chemical agents can be used for cancer diagnostic and therapeutic purposes. High selectivity, small size, and low immunogenicity of synthetic nucleic acid aptamers make them attractive delivery agents for therapeutic purposes. Properties, production and functionalization of magnetic nanoparticles and aptamers as ligands for targeted delivery are discussed herein. In recent years, magnetic nanoparticles have been widely used in diagnostic methods, such as scintigraphy, single photon emission computed tomography (SPECT), positron emission tomography (PET), magnetic resonance imaging (MRI), and Raman spectroscopy. Therapeutic purposes of magnetic nanoconstructions are also promising. They are used for effective drug delivery, magnetic mediated hypertermia, and megnetodynamic triggering of apoptosis. Thus, magnetic nanotheranostics opens a new venue for complex differential diagnostics, and therapy of metastatic cancer.Entities:
Keywords: aptamers; drug delivery; magnetic hyperthermia; magnetic nanoparticles; magnetodynamic therapy; magnetophoresis
Mesh:
Substances:
Year: 2017 PMID: 28604617 PMCID: PMC6152710 DOI: 10.3390/molecules22060975
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Illustration of superparamagnetic and ferromagnetic particles in the presence and absence of a magnetic field (MF), and after exposure to a MF. In the presence of an alternating magnetic field, the magnetic moment of both superparamagnetic and ferromagnetic nanoparticles are aligned. Upon removal of the magnetic field, the nanoparticles maintain the net magnetization.
Figure 2Size scale of MNS as compared to biomolecules.
Figure 3Schematic illustration of a multifunctional magnetic nanoparticle structure with different types of coatings, target ligands and imaging agents. Therapeutic drugs can be embedded in the coating, or conjugated on the surface.
Figure 4Modes of tumor-targeting magnetic nanoparticles. (A) Passive targeting (enhanced permeability and retention (EPR) effect) of magnetic nanoparticles. Nanoparticles reach tumor cells selectively through the leaky vasculature surrounding the tumors; (B) Active (molecular targeting). Ligands (aptamers, antibodies, peptides, small molecules, etc.) linked with magnetic nanoparticles that bind to receptors overexpressed by tumor cells; (C) Magnetic targeting.
Figure 5Schematic representation of the two mechanisms of controlled drug delivery using a magnetic field based hyperthermia. (a) Magnetic hyperthermia-based controlled drug delivery through enhanced permeability; (b) Magnetic hyperthermia-based controlled drug delivery through bond breaking (linkers).
Figure 6Principle of magnetic mediated hyperthermia. Targeted magnetic nanoparticles delivered to tumor cells are exposed to an alternating magnetic field (AMF). Afterword, AMF energy is converted into heat by the magnetic nanoparticles, which leads to local heating of tumor cells between 41 and 47 °C.
Figure 7The concept of targeted magnetomechanical cancer-cell destruction using magnetic nanoparticles with different shape.
Magnetic nanoparticles and their applications for a targeted cancer theranostics.
| Materials | Size | Coatings | Antitumor Drugs | Linkers | Targeted Ligands | Applications | Reference |
|---|---|---|---|---|---|---|---|
| Gd-DTPA | 123.2 nm | Thermo-sensitive liposome (DPPC) | - | Carboxyl groups | Aptamers | MRI | [ |
| Iron oxide (magnetite) | 51.43 ± 4.52 nm | - | Epirubicin | Amine, carboxyl groups | Aptamers | Targeted chemotherapy MRI | [ |
| Iron oxide (magnetite) | 10 nm | - | Dextran | Thiol groups | Aptamers | Magnetic hyperthermia | [ |
| Iron oxide (magnetite) | 12 ± 3 nm | - | Doxorubicin | Thiol groups | Aptamers | Magnetic hyperthermia computed tomography | [ |
| Ironoxide (magnetite) | 15.4 nm | Gold Polyethylene-glycol | - | Amino and thiol groups | Aptamers | Targeted magnetic hyperthermia | [ |
| Nickel magnetic microdisks | 500 nm | Gold | - | Thiol groups | Aptamers | Mechanical destruction of cells and triggering of apoptosis | [ |
| Iron oxide (magnetite) | 50nm | Gold | - | Thiol groups | Aptamers | Apoptosis induction via fibronectin binding aptamers | [ |
| Iron-tagged single-walled carbon nanotubes | 200–300 nm | Polyvinyl-pyrrolidone | Doxorubicin | Carboxyl groups | Antibodies | Targeted chemotherapy MRI | [ |
| Ironoxide (magnetite) | 10 nm | Polyethylene-glycol | - | Carboxylate and Amino groups | Antibodies | Targeted therapy MRI | [ |
| Ironoxide (magnetite) | 40 nm | Chitosan and polyethylene-glycol | - | Amino and thiol groups | Antibodies | MRI | [ |
| Mn-Zn ferrite MNCs | 42.3nm | Polyethylene-glycol | - | Carboxyl groups | Сyclic tripeptide of arginine-glycine-aspartic acid | Targeted magnetic hyperthermia MRI | [ |
| Ironoxide (magnetite) | 5 nm | Lipid bilayer (DPPC/PEG750-PE) | Doxorubicin | - | - | Targeted chemotherapy controlled by electromagnetic fields | [ |
| Ironoxide (magnetite) | 6.8 nm | Gold | Doxorubicin | Cystmolecules | - | Chemotherapy magnetic hyperthermia combinatorial treatment | [ |
| Iron oxide (magnetite, maghemite) | 16.1 nm | Mesoporous silica | Doxorubicin | - | - | Targeted chemotherapy and magnetic hyperthermia | [ |
| Iron Oxide Nanocubes | 19 nm | Polyethylene-glycol | - | - | - | Magnetic hyperthermia MRI | [ |
| Ironoxide (magnetite) | 14 nm | Phospholipid-Polyethylene-glycol coating | Doxorubicin | - | - | Chemotherapy-magnetic hyperthermia combinatorial treatment | [ |
| Ironoxide (magnetite) | 5 nm | - | Cytostatic mitox-antrone | Phosphate groups | - | Targeted chemotherapy controlled by strong inhomogeneous magnetic field | [ |